RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Langerhans Cell Histiocytosis: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Nine Years of Vemurafenib Therapy in BRAF V600E-Positive Multisystem Langerhans Cell Histiocytosis with Asymptomatic Neurodegenerative Changes.
Amal Elleuch et al., Indian journal of pediatrics (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42879086/
- 2.
Combination Therapy of Vinblastine, Prednisolone, Methotrexate, and 6-Mercaptopurine as a Front-Line Therapy for Adult Patients With Langerhans Cell Histiocytosis.
Sato Aki et al., American journal of hematology (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42875893/
- 3.
Feasibility of automated quantitative CT imaging metrics in pulmonary Langerhans cell histiocytosis: a pilot study
Amira Benattia et al., BMC Medical Imaging (13 October 2026)
https://doi.org/10.1186/s12880-026-02932-w
- 4.
Building bone in the jaw with denosumab in adult Langerhans cell histiocytosis.
Makras Polyzois et al., Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42867634/
- 5.
Stanford type A aortic dissection in long-standing Langerhans cell histiocytosis: a possible association.
Xiao Daoxiong et al., Acta cardiologica (9 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42853709/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069 · Recruiting · Phase 2 · National Cancer Institute (NCI)
Ages 180 Days to 22
https://clinicaltrials.gov/study/NCT05828069
- 2.
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04320888
- 3.
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04195555 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT04195555
- 4.
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT03213652
- 5.
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620 · Active (not recruiting) · Phase 2 · National Cancer Institute (NCI)
Ages 12 Months to 21
https://clinicaltrials.gov/study/NCT03155620
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Langerhans Cell Histiocytosis
Langerhans cell histiocytosis is a rare condition in which abnormal immune cells build up and form lesions in one or more parts of the body, most often the bones, skin, lungs, or pituitary gland. It can affect children and adults, and its severity ranges from a single bone lesion to widespread disease. Treatment depends on which organs are involved and may include observation, chemotherapy, or targeted medicines.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Langerhans Cell Histiocytosis?
Langerhans cell histiocytosis is a rare condition in which abnormal immune cells build up and form lesions in one or more parts of the body, most often the bones, skin, lungs, or pituitary gland. It can affect children and adults, and its severity ranges from a single bone lesion to widespread disease. Treatment depends on which organs are involved and may include observation, chemotherapy, or targeted medicines.
How many clinical trials are available for Langerhans Cell Histiocytosis?
RareWays currently indexes 58 clinical trials for Langerhans Cell Histiocytosis, of which 13 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Langerhans Cell Histiocytosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Langerhans Cell Histiocytosis.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.